Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
2020 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
Wachter, R. ; Shah, S. J.; Cowie, M. R.; Szecsödy, P.; Shi, V.; Ibram, G. & Zhao, Z. et al. (2020)
ESC Heart Failure, 7(3) pp. 856-864. DOI: https://doi.org/10.1002/ehf2.12694
